Evolus, Inc. (NASDAQ: EOLS) saw its price target lowered by Mizuho analyst Uy Ear to $15 from $19 on February 4 due to a softer-than-expected preannounced fourth quarter. Despite this adjustment, the company remains confident in Evolus’ long-term growth trajectory and competitive position in the medical aesthetics market.

Evolus, Inc. (NASDAQ: EOLS) reported solid operational momentum in the third quarter of 2025 with $69 million in revenue, representing 13% year-over-year growth. Global demand for Jeuveau and the U.S. launch of Evolysse have been key drivers, showcasing the company’s ability to execute across different product offerings and markets.

Evolus, Inc. (NASDAQ: EOLS) operates as a performance beauty company specializing in injectable aesthetic treatments. With a focus on expanding its portfolio and international presence, the company is well-positioned for long-term growth. Based in Newport Beach, California, Evolus is poised to capitalize on global demand trends and drive revenue growth.

Although Evolus (NASDAQ: EOLS) shows investment potential, other AI stocks may offer greater upside with less risk. For those seeking opportunities in the AI sector, consider exploring the free report on the best short-term AI stock. Stay informed about evolving market trends and investment opportunities with Insider Monkey’s latest articles on up-and-coming streaming companies and high-growth Canadian stocks.

Read more at Yahoo Finance: Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating